Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04924062
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-26
First Post:
2021-06-08
Brief Title:
Pembrolizumab MK-3475 Plus GemcitabineCisplatin Versus Placebo Plus GemcitabineCisplatin for First-Line Advanced andor Unresectable Biliary Tract Carcinoma BTC MK-3475-966KEYNOTE-966-China Extension Study
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Organization Data
Organization:
Merck Sharp Dohme LLC
Class:
INDUSTRY
Study ID:
3475-966 China Extension
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck Sharp Dohme LLC
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None